
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
Developments in 2002 such as acquisitions, excess manufacturing capacity, and less funding for biotechnology will continue to affect the industry long into the new year.
over 23 years ago
Pharmaceutical Pricing and Innovation Key Issues for 2003over 23 years ago
Procedures: Improving Their Qualityover 23 years ago
Drug-Carrier Screening on a Chipover 23 years ago
Pack EXPO International 2002 Proves Worth the Tripover 23 years ago
Analysis of the Indian Pharmaceutical Industry